Drug intelligence / Profile preview

cx2101a

Development stage: Phase 1
Lead developer: China Resources Double-Crane Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

CX2101A is a small molecule drug developed as an RNA-directed RNA polymerase (RdRp) inhibitor. It was initially developed by Ligand Pharmaceuticals and is currently being investigated for the treatment of COVID-19 pneumonia. The drug acts by inhibiting viral replication through targeting the RdRp enzyme, which is essential for the replication of SARS-CoV-2 and other RNA viruses[1][7]. Clinical development has reached Phase 1 in China, with studies focusing on safety, tolerability, pharmacokinetics, and bioavailability in healthy adult subjects[4][5].

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on cx2101a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cx2101a.

Explore the full profile